Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | Biomarkers in lymphoma

Arjan Diepstra • 15 Jun 2018
EHA 2018
Hodgkin Lymphoma Lymphoma

In this interview with Arjan Diepstra, PhD, from the University of Groningen, Groningen, Netherlands, speaking from the 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden, gives a brief overview of the role of biomarkers in lymphoma. Dr Diepstra covers how they can be used to determine patient prognosis and influence clinical decisions. He highlights the TARC biomarker currently being used in Hodgkin lymphoma.

More from Arjan Diepstra

3:54
The use of TARC as a diagnostic biomarker in Hodgkin lymphoma
Arjan Diepstra • 26 Oct 2022
0:54
The role of CD4+ T-cells in the pathogenesis of Hodgkin lymphoma
Arjan Diepstra • 26 Oct 2022
1:15
Biomarkers being explored in Hodgkin lymphoma: the role of ctDNA
Arjan Diepstra • 26 Oct 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals